<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Schering-Plough &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/schering-plough/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Tue, 16 Aug 2022 12:22:13 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>Schering-Plough &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2021-2025年中国替莫唑胺市场研究报告:2016-2020年的CAGR为9.04%</title>
		<link>https://www.yuanzhezixun.com/2021-2025nianzhongguotimozuoansh/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Thu, 08 Jul 2021 08:26:27 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[Merck Sharp & Dohme]]></category>
		<category><![CDATA[MSD]]></category>
		<category><![CDATA[Schering-Plough]]></category>
		<category><![CDATA[TEMODAL]]></category>
		<category><![CDATA[交宁]]></category>
		<category><![CDATA[先灵葆雅]]></category>
		<category><![CDATA[化疗药物]]></category>
		<category><![CDATA[双鹭药业]]></category>
		<category><![CDATA[口服化疗药物]]></category>
		<category><![CDATA[天士力帝益药业]]></category>
		<category><![CDATA[恒瑞医药]]></category>
		<category><![CDATA[恶性神经胶质瘤]]></category>
		<category><![CDATA[恶性黑色素瘤]]></category>
		<category><![CDATA[抗癌药]]></category>
		<category><![CDATA[抗肿瘤药]]></category>
		<category><![CDATA[替莫唑胺]]></category>
		<category><![CDATA[替莫唑胺区域分析]]></category>
		<category><![CDATA[替莫唑胺市场份额]]></category>
		<category><![CDATA[替莫唑胺市场竞争]]></category>
		<category><![CDATA[替莫唑胺市场细分]]></category>
		<category><![CDATA[替莫唑胺市场规模]]></category>
		<category><![CDATA[泰道]]></category>
		<category><![CDATA[烷化剂]]></category>
		<category><![CDATA[脑癌]]></category>
		<category><![CDATA[蒂清]]></category>
		<category><![CDATA[默沙东]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=24776</guid>

					<description><![CDATA[替莫唑胺属于第二代烷化剂，是一种口服化疗药物，用于治疗成人恶性神经胶质瘤和恶性黑色素瘤等脑癌。CRI元哲的调研数据显示，2016-2019年中国市场的替莫唑胺销售额逐年增加。2020年由于新冠疫情，中国市场替莫唑胺销售额下降到7.93亿元， 2016-2020年的CAGR为9.04%。CRI元哲预计在2021-2025年随着新冠疫情的缓解，中国市场替莫唑胺销售额将有恢复性的增长。<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
